HALO
Halozyme Therapeutics Inc
Price:  
56.23 
USD
Volume:  
831,949.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

HALO WACC - Weighted Average Cost of Capital

The WACC of Halozyme Therapeutics Inc (HALO) is 8.8%.

The Cost of Equity of Halozyme Therapeutics Inc (HALO) is 9.85%.
The Cost of Debt of Halozyme Therapeutics Inc (HALO) is 4.30%.

Range Selected
Cost of equity 8.40% - 11.30% 9.85%
Tax rate 11.30% - 18.90% 15.10%
Cost of debt 4.00% - 4.60% 4.30%
WACC 7.5% - 10.0% 8.8%
WACC

HALO WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.99 1.15
Additional risk adjustments 0.0% 0.5%
Cost of equity 8.40% 11.30%
Tax rate 11.30% 18.90%
Debt/Equity ratio 0.22 0.22
Cost of debt 4.00% 4.60%
After-tax WACC 7.5% 10.0%
Selected WACC 8.8%